EGFR and lung adenocarcinoma: While targetable driver mutations (e.g., EGFR, BRAF) and translocations/fusions (e.g., ALK, ROS, RET) are frequently detected in lung adenocarcinoma (see next paragraph), they are rare (<1%) in squamous cell carcinoma and neuroendocrine neoplasms.